Kyowa Kirin pharma growth lacklustre despite strong Nesp sales
This article was originally published in Scrip
Despite good growth for mainstay product Nesp (darbepoetin alfa; licensed from Amgen), net pharmaceutical sales at Kyowa Hakko Kirin rose by just 1% to ¥210.4 billion ($2.56 billion) in calendar 2010, held back mainly by last April's general reimbursement price cut in Japan.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.